Details

Autor(en) / Beteiligte

• Dilliott, Allison A.
• Sunderland, Kelly M.
• McLaughlin, Paula M.
• Roberts, Angela C.
• Evans, Emily C.
• Abrahao, Agessandro
• Binns, Malcolm A.
• Black, Sandra E.
• Borrie, Michael
• Casaubon, Leanne.K.
• Dowlatshahi, Dar
• Finger, Elizabeth
• Fischer, Corinne.E.
• Frank, Andrew
• Freedman, Morris
• Grimes, David
• Hassan, Ayman
• Jog, Mandar
• Kumar, Sanjeev
• Kwan, Donna
• Lang, Anthony E.
• Mandzia, Jennifer
• Marras, Connie
• Masellis, Mario
• McIntyre, Adam D.
• Pasternak, Stephen
• Pollock, Bruce G.
• Rajji, Tarek K.
• Robinson, John F.
• Rogaeva, Ekaterina
• Sahlas, Demetrios J.
• Saposnik, Gustavo
• Sato, Christine
• Seitz, Dallas
• Shoesmith, Christen
• Steeves, Thomas
• Strother, Stephen C.
• Swartz, Richard H.
• Tan, Brian
• Tang-Wai, David
• Tartaglia, Maria C.
• Troyer, Angela K.
• Turnbull, John
• Zinman, Lorne
• Hegele, Robert A.

Titel

Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses

Ist Teil von

• Neurobiology of aging, 2021-09, Vol.105, p.378.e1-378.e9

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• •APOE and cognition was assessed across multiple neurodegenerative disease cohorts.•APOE E4 was associated with worse verbal memory and visuospatial performance.•APOE E2 was only associated with worse cognitive function in the FTD cohort.•Influence of APOE on cognition is complex and may vary based on diagnosis. For many years there has been uncertainty regarding how apolipoprotein E (APOE) E2 and E4 variants may influence overlapping features of neurodegeneration, such as cognitive impairment. We aimed to identify whether the APOE variants are associated with cognitive function across various neurodegenerative and cerebrovascular diagnoses (n = 513). Utilizing a comprehensive neuropsychology battery, multivariate multiple regression was used to assess the influence of APOE carrier status and disease cohort on performance across five cognitive domains. Irrespective of disease cohort, E4 carriers had significantly lower performance in verbal memory and visuospatial domains than those with E3/3, while E2 carriers’ cognitive performance was not significantly different. However, E2 carriers with frontotemporal dementia (FTD) performed significantly worse than those with E3/3 in the attention/working memory, executive function, and visuospatial domains. Our results highlight that the influence of APOE variation on cognition is complex, in some cases varying based on diagnosis and possibly underlying disease pathology.